Table 1.

Approved treatment regimens for monoclonal antibodies in mCRC.

Antibody	FDA-approved regimens	EMA-approved regimens
Bevacizumab	In combination with i.v. 5-FU-based chemotherapy for first- or second-line treatment	In combination with fluoropyrimidine-based chemotherapy
Cetuximab	As a single agent in EGFR-expressing mCRC after failure of both irinotecan- and oxaliplatin-based regimens or in patients who are intolerant to irinotecan-based regimens In combination with irinotecan in EGFR-expressing mCRC in patients who are refractory to irinotecan-based chemotherapy Not recommended for the treatment of mCRC with KRAS mutations in codons 12 or 13	In combination with chemotherapy or as a single agent in patients with EGFR-expressing, KRAS wild-type mCRC who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan
Panitumumab	Single agent for EGFR-expressing mCRC with disease progression or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens Not recommended for the treatment of mCRC with KRAS mutations in codons 12 or 13	Monotherapy in EGFR-expressing mCRC with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens

EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; 5-FU, 5-fluorouracil; i.v., intravenous; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; mCRC, metastatic colorectal cancer.

Sources: http://www.emea.europa.eu/, http://www.fda.gov/.